106 related articles for article (PubMed ID: 7551245)
1. Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant.
Coughlin RT; Ma J; Cox DE
Pharm Biotechnol; 1995; 6():719-35. PubMed ID: 7551245
[No Abstract] [Full Text] [Related]
2. NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies.
Huang X; Yang X; Luft BJ; Koide S
J Mol Biol; 1998 Aug; 281(1):61-7. PubMed ID: 9680475
[TBL] [Abstract][Full Text] [Related]
3. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
4. [Lyme borreliosis--vaccines in the "pipeline"].
Kramer M
MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
[No Abstract] [Full Text] [Related]
5. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
6. Studies on OspA: a source of new paradigms in Lyme disease research.
Philipp MT
Trends Microbiol; 1998 Feb; 6(2):44-7. PubMed ID: 9507636
[No Abstract] [Full Text] [Related]
7. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
8. [Lyme disease vaccine: hopes and concerns].
Kondrusik M; Zajkowska J; Pancewicz S; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 1999 Jun; 6(36):344-6. PubMed ID: 10481552
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of Lyme disease].
Kondrusik M; Zajkowska J; Pancewicz S; Hermanowska-Szpakowicz T
Med Pr; 1999; 50(4):321-4. PubMed ID: 10582211
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
13. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans.
Philipp MT; Bowers LC; Fawcett PT; Jacobs MB; Liang FT; Marques AR; Mitchell PD; Purcell JE; Ratterree MS; Straubinger RK
J Infect Dis; 2001 Oct; 184(7):870-8. PubMed ID: 11550127
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of test with antigen VlsE (C6) with tests with recombinant antigens in patients with Lyme borreliosis].
Zajkowska JM; Kondrusik M; Pancewicz SA; Grygorczuk S; Jamiołkowski J; Stalewska J
Pol Merkur Lekarski; 2007 Aug; 23(134):95-9. PubMed ID: 18044336
[TBL] [Abstract][Full Text] [Related]
15. Protection from Lyme neuroborreliosis in nonhuman primates with a multiantigenic vaccine.
Pachner AR; Delaney E; Zhang WF; O'Neill T; Major E; Frey AB; Davidson E
Clin Immunol; 1999 Jun; 91(3):310-3. PubMed ID: 10370376
[TBL] [Abstract][Full Text] [Related]
16. Statement on immunization for Lyme disease (ACS-3). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI).
Can Commun Dis Rep; 2000 Jul; 26():1-11. PubMed ID: 10927837
[No Abstract] [Full Text] [Related]
17. Lyme disease vaccine (Pasteur Mérieux Connaught). ImuLyme.
Drugs R D; 1999 Sep; 2(3):211-2. PubMed ID: 10641231
[No Abstract] [Full Text] [Related]
18. Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.
Ledue TB; Collins MF; Young J; Schriefer ME
Clin Vaccine Immunol; 2008 Dec; 15(12):1796-804. PubMed ID: 18945880
[TBL] [Abstract][Full Text] [Related]
19. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL.
Liang FT; Aberer E; Cinco M; Gern L; Hu CM; Lobet YN; Ruscio M; Voet PE; Weynants VE; Philipp MT
J Infect Dis; 2000 Nov; 182(5):1455-62. PubMed ID: 11023468
[TBL] [Abstract][Full Text] [Related]
20. Availability of Lyme disease vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
